Detail
| LncRNA Name | BALR-2 |
| Synonyms | NA |
| Region | NA Sequence |
| Ensembl | NA |
| RefSeq | NA |
| Circulating | ✔ |
| Drug-resisitant | ✔ |
| Prognostic | ✔ |
| MiRNA | ✔ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | B-lymphoblastic leukemia |
| ICD-0-3 | M9811/3 |
| Methods | microarray, qPCR, Western blot etc. |
| Sample | blood, cell line (HEK 293T) |
| Expression Pattern | differential expression |
| Function Description | high expression of BALR-2 correlated with poor overall survival and diminished response to prednisone treatment. In line with a function for this lncRNA in regulating cell survival, BALR-2 knockdown led to reduced proliferation, increased apoptosis, and increased sensitivity to prednisolone treatment. Conversely, overexpression of BALR-2 led to increased cell growth and resistance to prednisone treatment. Interestingly, BALR-2 expression was repressed by prednisolone treatment and its knockdown led to upregulation of the glucocorticoid response pathway in both human and mouse B-cells |
| Pubmed ID | 25681502 |
| Year | 2015 |
| Title | LncRNA Expression Discriminates Karyotype and Predicts Survival in B-Lymphoblastic Leukemia |
| External Links |
| Links for BALR-2 | GenBank HGNC lncrnadb Noncode |
| Links for B-lymphoblastic leukemia | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.